External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China

Lou, Tao; Li, Bin; Xiong, Pian; Jin, Caiting; Chen, Yagang

doi:10.1111/jvh.13569

Cited by 5 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,43,44 A recent study performed external validations to compare the predictability of REACH-B, PAGE-B, mPAGE-B and CU-HCC in patients with CHB in China and the AUROCs of those scores ranged from 0.703 to 0.825. 45 Compared to previous studies, our model includes a larger number of NAtreated patients, includes more comprehensive partitioned indicators which were convenient for practical application, and achieves better detection performance for HBVrelated HCC especially in NA-treated patients. It is worth mentioning that our model was validated to be able to detect early-stage (BCLC-0/A) HCC with relatively good AUROC and fitting effect, which will further help in the early diagnosis and early treatment of HBVrelated HCC.…”

mentioning

confidence: 99%

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram

Sun

Qiu

et al. 2021

IJGM

View full text Add to dashboard Cite

Background The thresholds of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (PIVKA-II) when detecting hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with antiviral nucleoside analog (NA) remain controversial. A relevant integrated nomogram needs to be developed. Methods We enrolled a consecutive series of 5666 cases diagnosed with CHB either with or without antiviral agents and randomly allocated them to the training set (n=3966, 70.00%) and the validation set (n=1700, 30.00%). Results In the training set, the levels of AFP and PIVKA-II of NA-treated patients were significantly lower than those of untreated patients. The most appropriate cut-off values of AFP and PIVKA-II were 151.40 ng/mL (a sensitivity of 39.77% and a specificity of 92.17%) and 35.50 mAU/mL (a sensitivity of 84.85% and a specificity of 69.43%) for NA-treated patients. As for BCLC-0/A HCC, the most appropriate cut-off values of AFP and PIVKA-II were 151.40 ng/mL and 32.50 mAU/mL for NA-treated patients, respectively. A logistic regression model composed of AFP, PIVKA-II and other clinical parameters to predict the risk of HBV-related HCC for NA-treated patients was established and verified to have an AUROC of 0.868 (95% CI, 0.827–0.909) for all-stage HCC and an AUROC of 0.856 (95% CI, 0.809–0.903) for BCLC-0/A HCC. Conclusion The new detection thresholds of AFP and PIVKA-II might lead to the ability to perform early detection for hepatoma in NA-treated patients and the innovative risk prediction model is a valuable tool for identifying high-risk CHB patients.

show abstract

mentioning

confidence: 99%

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram

Sun

Qiu

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…Primary liver cancer is among the most commonly diagnosed cancers, most of which are HCC[ 65 , 66 ]. Due to the high infection rate of hepatitis B virus, the incidence of HCC in China remains high[ 67 ]. Surgical resection of the liver is the main treatment for HCC.…”

Section: Immunotherapy-based Novel Nanoparticles In Hccmentioning

confidence: 99%

Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges

Ding¹,

Xue²,

Tang³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

Gastrointestinal cancer (GIC) is the most common cancer with a poor prognosis. Currently, surgery is the main treatment for GIC. However, the high rate of postoperative recurrence leads to a low five-year survival rate. In recent years, immunotherapy has received much attention. As the only immunotherapy drugs approved by the Food and Drug Administration (FDA), immune checkpoint blockade (ICB) drugs have great potential in cancer therapy. Nevertheless, the efficacy of ICB treatment is greatly limited by the low immunogenicity and immunosuppressive microenvironment of GIC. Therefore, the targets of immunotherapy have expanded from ICB to increasing tumor immunogenicity, increasing the recruitment and maturation of immune cells and reducing the proportion of inhibitory immune cells, such as M2-like macrophages, regulatory T cells and myeloid-derived suppressor cells. Moreover, with the development of nanotechnology, a variety of nanoparticles have been approved by the FDA for clinical therapy, so novel nanodrug delivery systems have become a research focus for anticancer therapy. In this review, we summarize recent advances in the application of immunotherapy-based nanoparticles in GICs, such as gastric cancer, hepatocellular carcinoma, colorectal cancer and pancreatic cancer, and described the existing challenges and future trends.

show abstract

Constitutive photomorphogenic protein 1 ubiquitinates interleukin-1 receptor accessory protein in human liver cancer

Cao,

Liu,

Liu

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China

Cited by 5 publications

References 32 publications

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram

Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges

Constitutive photomorphogenic protein 1 ubiquitinates interleukin-1 receptor accessory protein in human liver cancer

Contact Info

Product

Resources

About